KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Current Deferred Revenue (2016 - 2020)

Nektar Therapeutics (NKTR) has 11 years of Current Deferred Revenue data on record, last reported at $91000.0 in Q4 2020.

  • For Q4 2020, Current Deferred Revenue fell 98.35% year-over-year to $91000.0; the TTM value through Dec 2020 reached $91000.0, down 98.35%, while the annual FY2020 figure was $91000.0, 98.35% down from the prior year.
  • Current Deferred Revenue reached $91000.0 in Q4 2020 per NKTR's latest filing, down from $507000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $38.0 million in Q4 2017 and bottomed at $91000.0 in Q4 2020.
  • Average Current Deferred Revenue over 5 years is $16.3 million, with a median of $14.8 million recorded in 2016.
  • Peak YoY movement for Current Deferred Revenue: surged 164.56% in 2017, then tumbled 98.35% in 2020.
  • A 5-year view of Current Deferred Revenue shows it stood at $14.4 million in 2016, then soared by 164.56% to $38.0 million in 2017, then crashed by 63.41% to $13.9 million in 2018, then tumbled by 60.29% to $5.5 million in 2019, then crashed by 98.35% to $91000.0 in 2020.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $91000.0 in Q4 2020, $507000.0 in Q3 2020, and $1.8 million in Q2 2020.